Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 08, 2022 16:05 ET
|
Gritstone bio
EMERYVILLE, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Earns 2022 Great Place to Work Certification™
June 02, 2022 08:00 ET
|
Gritstone bio
EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of GRANITE and Trial in Progress Poster at ASCO
May 31, 2022 08:00 ET
|
Gritstone bio
-- Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response as presented at ESMO 2021 will...
Gritstone to Participate in H.C. Wainwright Global Investment Conference
May 17, 2022 17:00 ET
|
Gritstone bio
EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced...
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
May 06, 2022 19:30 ET
|
Gritstone bio
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines...
Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022 16:05 ET
|
Gritstone bio
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines...
Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Opportunity for Shareholders
May 02, 2022 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 27, 2022 16:05 ET
|
Gritstone bio
EMERYVILLE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery
April 12, 2022 16:35 ET
|
Gritstone bio
-- Translational immunology data and cassette design capabilities enabled development of an optimized, KRAS-specific version of “off-the-shelf” vaccine candidate now in Phase 2 (SLATE-KRAS) -- --...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 30, 2022 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...